Amati M, Tomasetti M, et al.
Cancer Epidemiol Biomarkers Prev. 2008;17(1):163-170.
Amati and colleagues investigated biomarkers in the detection of Malignant mesothelioma. The biomarkers were tested in 94 asbestos exposed patients, 54 age-matched controls and 22 patients diagnosed with malignant mesothelioma.
The following markers were tested in all 170 patients: MESOMARK (SMRP), 8OHdG in circulating WBCs, angiogenic factors (PDGFβ, HGF, bFGF and VEGFβ), MMPs (MMP2 and MMP9) and their inhibitors (TIMP1 and TIMP2). Results show high levels of 8OHdG and SMRP in the mesothelioma group when compared to healthy controls. ROC curves were compared for individual markers and SMRP resulted in the highest AUC between mesothelioma patients and controls (0.920) and asbestos exposed from mesothelioma patients (0.927). The authors propose the use of SMRP for use in diagnosis of mesothelioma.
SMRP had the highest sensitivity and specificity; other markers tested were able to identify high-risk patients from healthy and mesothelioma. The combination of 8OHdG and VEGFβ greatly increased the sensitivity and specificity and enabled researchers to identify high-risk from healthy controls. These three markers in combination are best able to discriminate between the groups (asbestos exposed, mesothelioma and controls). Researchers conclude that these markers may, together with radiography, be able to stratify patients into risk groups for continued follow-up and ultimately the early diagnosis of malignant mesothelioma.